Oxyduo is a prolonged-release tablet, which means that the active substances are released over a prolonged period. Their effect lasts for 12 hours.
These tablets are for use in adults only.
Oxyduo is indicated for the treatment of severe pain, which can only be adequately managed with opioid analgesics.
How Oxyduo works to relieve pain
Oxyduo contains two active substances: oxycodone hydrochloride and naloxone hydrochloride.
Oxycodone hydrochloride is responsible for the analgesic effect of Oxyduo and is a strong opioid analgesic.
Before taking Oxyduo, tell your doctor or pharmacist:
Tell your doctor if you experience severe abdominal pain which may radiate to your back, nausea, vomiting or fever, as these may be signs of pancreatitis or bile duct problems.
Sleep apnoea syndrome
Oxyduo may cause sleep apnoea syndrome (pauses in breathing during sleep) and hypoxia during sleep (low oxygen levels in the blood). Symptoms may include pauses in breathing during sleep, waking up during the night due to shortness of breath, difficulty staying asleep or excessive daytime sleepiness. If you or someone else notices these symptoms, you should contact your doctor. Your doctor may consider reducing the dose.
Consult your doctor if you have experienced these symptoms in the past.
Also, consult your doctor if you develop any of these problems while taking Oxyduo. The most serious side effect of overdose of opioid analgesics is respiratory depression(slow and shallow breathing). This can lead to a reduction in the amount of oxygen in the blood, which can cause loss of consciousness.
Switching to Oxyduo
When switching to Oxyduo after long-term treatment with another opioid, you may initially experience withdrawal symptoms, such as restlessness, particularly agitation, sweating and muscle pain. If you experience these symptoms, you may need special medical supervision.
Tolerance, dependence and addiction
This medicine contains oxycodone, which is an opioid. It can cause addiction and (or) dependence.
This medicine contains oxycodone, which is an opioid analgesic. Repeated use of opioid analgesics may lead to physical dependence and (or) addiction.
Repeated use of Oxyduo may lead to dependence and (or) addiction, which can be life-threatening. The risk of these side effects may increase with dose and duration of treatment.
Dependence and (or) addiction can happen in anyone taking this medicine. The risk of dependence and (or) addiction is higher for those who:
If you experience any of the following symptoms while taking Oxyduo, it may mean that you are becoming dependent on or addicted to it:
If you experience any of these symptoms, you should contact your doctor. Your doctor will be able to advise you on the best course of action to take.
Oxyduo is not intended for the treatment of withdrawal symptoms.
Prolonged-release tablets can be divided into equal doses but must not be chewed or crushed. Taking a chewed or crushed tablet can lead to the absorption of a potentially fatal dose of oxycodone hydrochloride (see section 3, "Taking a higher dose of Oxyduo than prescribed").
Abuse
Never abuse Oxyduo, especially if you are dependent on substances such as heroin, morphine or methadone. Abuse of Oxyduo in people who are dependent on substances can lead to severe withdrawal symptoms, as Oxyduo contains naloxone. Previous withdrawal symptoms may be intensified.
Incorrect use
Do not misuse Oxyduo prolonged-release tablets by dissolving and injecting the tablet contents (e.g. into a vein). The tablets contain talc, which can cause local tissue necrosis (death of tissue) and lung tissue changes (pulmonary granulomas). Such abuse can also lead to other serious consequences, including death.
Doping
Taking Oxyduo may result in a positive test for doping substances. Taking Oxyduo as a doping substance can be a risk to your health.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
The risk of side effects increases if you are taking medicines for depression (such as citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine). These medicines can interact with oxycodone, which may cause symptoms such as involuntary, rhythmic muscle contractions, excitement, excessive sweating, tremors, increased reflexes, increased muscle tone, and elevated body temperature above 38°C. If you experience these symptoms, you should contact your doctor.
Concomitant use of opioids, including oxycodone hydrochloride, and sedatives, such as benzodiazepines or similar drugs, increases the risk of drowsiness, breathing difficulties (respiratory depression), coma and may be life-threatening. For this reason, concomitant use should only be considered when other treatment options are not possible.
If your doctor has prescribed Oxyduo together with sedatives, they will limit the dose and duration of concomitant treatment.
Tell your doctor about all sedatives you are taking and follow your doctor's advice on dose carefully. It may be helpful to inform friends or relatives about the sedative effects of these medicines. If you experience these symptoms, you should contact your doctor. Examples of these sedatives or similar medicines are:
If you are taking any of these medicines, the effects of Oxyduo or the other medicine may be altered. Tell your doctor if you are taking:
No interaction with paracetamol, acetylsalicylic acid (aspirin) or naltrexone is expected.
Drinking alcohol while taking Oxyduo may cause drowsiness or increase the risk of serious side effects, such as shallow breathing and loss of consciousness. Drinking alcohol while taking Oxyduo is not recommended.
Do not drink grapefruit juice while taking Oxyduo.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Oxyduo should not be used during pregnancy unless absolutely necessary. Long-term use of Oxyduo during pregnancy may cause withdrawal symptoms in the newborn baby. If oxycodone hydrochloride is used during delivery, it may cause respiratory depression (slow and shallow breathing) in the newborn baby.
Breast-feeding
You should not breast-feed while taking Oxyduo. Oxycodone hydrochloride passes into breast milk. It is not known whether naloxone hydrochloride also passes into breast milk. Therefore, a risk to the breast-fed child cannot be excluded, especially if Oxyduo is taken repeatedly.
Oxyduo may affect your ability to drive or use machines, as it may cause drowsiness and dizziness. This is especially likely at the start of treatment, after each dose increase or when switching to a different opioid. However, if you have been taking the same dose of Oxyduo for some time, these effects should be minimal.
Oxyduo has been associated with drowsiness and sudden sleep attacks. If you experience this side effect, you should not drive or operate machinery.
Discuss with your doctor whether you can drive or use machines.
Oxyduo contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, which is essentially sodium-free.
Always take this medicine exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist.
Before starting treatment and regularly during treatment, your doctor will discuss with you how you are feeling and what you can expect when taking Oxyduo, when and how to take it, when to contact your doctor and when to stop taking it (see also "Stopping Oxyduo").
Oxyduo is a prolonged-release tablet, which means that the active substances are released over a prolonged period. Their effect lasts for 12 hours.
Taking a higher dose of Oxyduo than prescribed
Pain relief
Adults
Usual starting dose is one 10 mg oxycodone hydrochloride + 5 mg naloxone hydrochloride prolonged-release tablet every 12 hours.
Your doctor will decide what dose of Oxyduo you should take each day and how to divide your daily dose into morning and evening doses. Your doctor will also decide on any necessary dose adjustments during treatment. Your doctor will adjust the dose according to the severity of your pain and your individual sensitivity.
You should be given the lowest effective dose for the relief of your pain.
Oxyduo has not been studied in children and adolescents under 18 years. The safety and efficacy of Oxyduo in children and adolescents have not been established. Therefore, Oxyduo should not be used in children and adolescents under 18 years.
Oral use. Oxyduo should be swallowed whole with a sufficient amount of liquid (half a glass of water). The tablet can be divided into equal doses but must not be chewed or crushed.
Oxyduo can be taken with or without food.
Oxyduo should be taken every 12 hours, according to the established treatment schedule (e.g. in the morning at 8:00, in the evening at 20:00).
Oxyduo should not be taken for longer than necessary. If you are taking Oxyduo for a long time, your doctor will regularly check whether you still need it.
If you take more Oxyduo than you should, contact your doctor immediately.
Overdose may cause:
Avoid activities that require increased attention, such as driving.
If you miss a dose of Oxyduo or take a lower dose than prescribed, you may not feel any effect of the medicine.
If you forget to take a dose, follow the instructions below:
Do not take more than one dose in 8 hours.
Do not take a double dose to make up for a forgotten dose.
Do not stop taking Oxyduo without consulting your doctor. If treatment is no longer necessary, your doctor will tell you how to reduce your dose gradually. This will help prevent withdrawal symptoms, such as restlessness, sweating and muscle pain.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you experience any of the following serious side effects, contact your doctor immediately.
Shallow breathing (respiratory depression) is the main risk of overdose of opioid analgesics. It usually occurs in elderly or debilitated patients. Opioids can also cause a significant drop in blood pressure in susceptible patients.
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Frequency not known(frequency cannot be estimated from the available data)
Oxycodone can cause breathing problems (respiratory depression), pinpoint pupils, bronchospasm and spasms of the smooth muscles and a reduction in the cough reflex.
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Frequency not known(frequency cannot be estimated from the available data)
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Frequency not known(frequency cannot be estimated from the available data)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in the "Further information" section below.
By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children. This medicine should be stored in a locked and secure location, out of the reach of others. It can be very harmful and may cause death if taken by someone for whom it has not been prescribed.
Do not use this medicine after the expiry date which is stated on the packaging, label and blister after EXP. The expiry date refers to the last day of that month.
Blister: Store in a temperature not exceeding 25°C.
Bottles: Store in a temperature not exceeding 30°C.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
The active substances are oxycodone hydrochloride and naloxone hydrochloride.
Each prolonged-release tablet contains 40 mg oxycodone hydrochloride (equivalent to 36 mg oxycodone) and 20 mg naloxone hydrochloride (as 21.8 mg naloxone hydrochloride dihydrate, equivalent to 18 mg naloxone).
The other ingredients are:
Tablet core
Polyvinyl acetate, povidone, sodium lauryl sulfate, colloidal anhydrous silica, microcrystalline cellulose and magnesium stearate.
Tablet coating
Polyvinyl alcohol, titanium dioxide (E171), macrogol, talc and iron oxide red (E172).
Pink, oval, biconvex prolonged-release tablet with a score line on both sides, 14.2 mm in length, 6.7 mm in width and 3.6-4.6 mm in height.
The tablet can be divided into equal doses.
Oxyduo is available in:
Child-resistant blisters containing 10, 14, 20, 28, 30, 50, 56, 60, 90, 98 or 100 prolonged-release tablets; child-resistant single-dose perforated blisters containing 56 x 1 or 60 x 1 prolonged-release tablets; or child-resistant bottles containing 50, 100, 200 or 250 prolonged-release tablets.
Not all pack sizes may be marketed.
Teva Pharmaceuticals Polska Sp. z o.o.
ul. Emilii Plater 53
00-113 Warszawa
tel.: (22) 345 93 00
1/ Develco Pharma GmbH
Grienmatt 27, Schopfheim 79650, Germany
2/ PLIVA Hrvatska d.o.o. (Pliva Croatia Ltd.), Prilaz baruna Filipovića 25
10000 Zagreb, Croatia
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.